Finance

Lists
4502:TYO
Takeda Pharmaceutical Co Ltd
5 270,00 JPY
-0,30%
(-16,00) 1D
5 აგვ, 13:31:23 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4502...
Open
5 234 JPY
High
5 284 JPY
Low
5 225 JPY
Mkt. cap
8,44 ტრლ.
Avg. vol.
4,05 მლნ.
Volume
1,82 მლნ.
Dividend
3,80%
Quarterly dividend
50 JPY
Ex-dividend date
29 სექ. 2026
52-wk high
6 033 JPY
52-wk low
4 102 JPY
EPS
-103 JPY
Shares outstanding
784,48 მლნ.
No. of employees
47 ათ.
Open
5 234 JPY
High
5 284 JPY
Low
5 225 JPY
Mkt. cap
8,44 ტრლ.
Avg. vol.
4,05 მლნ.
Volume
1,82 მლნ.
Dividend
3,80%
Quarterly dividend
50 JPY
Ex-dividend date
29 სექ. 2026
52-wk high
6 033 JPY
52-wk low
4 102 JPY
EPS
-103 JPY
Shares outstanding
784,48 მლნ.
No. of employees
47 ათ.
News stories
From sources across the web
marketscreener.com
marketscreener.com
·
12 წუთის წინ
Semis fly again as AI capex shoots the moon
Seeking Alpha
Seeking Alpha
·
21 წუთის წინ
Michael Burry warns of 1987-style crash even as S&P 500 hits new high
marketscreener.com
marketscreener.com
·
23 წუთის წინ
The S&P 500 index rose after the Stockholm stock market closed on Tuesday
Investor's Business Daily
Investor's Business Daily
·
1 საათის წინ
Dow Jones Futures Rise; SpaceX, AMD, Arista Lead Earnings Movers After S&P 500 Jumps To High
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOკრისტოფ ვებერი | კრისტოფ ვებერი
Employees47 ათ.
Founded12 ივნ. 1781
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Last report
30 ივლ. 2026
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
1,22 ტრლ. / 1,15 ტრლ.
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,11 ტრლ.
1,19 ტრლ.
1,09 ტრლ.
1,22 ტრლ.
Cost of goods sold
380,06 მლრ.
401,15 მლრ.
453,33 მლრ.
406,68 მლრ.
Cost of revenue
380,06 მლრ.
401,15 მლრ.
453,33 მლრ.
406,68 მლრ.
Research and development expenses
161,48 მლრ.
175,23 მლრ.
187,96 მლრ.
167,40 მლრ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
253,55 მლრ.
282,78 მლრ.
291,96 მლრ.
286,51 მლრ.
Operating expense
562,57 მლრ.
661,30 მლრ.
519,65 მლრ.
612,60 მლრ.
Total operating expenses
942,63 მლრ.
1,06 ტრლ.
972,98 მლრ.
1,02 ტრლ.
Operating income
170,17 მლრ.
129,25 მლრ.
121,56 მლრ.
200,62 მლრ.
Other non operating income
77,96 მლრდ.
-197,22 მლრ.
181,53 მლრ.
-28,14 მლრდ.
EBT including unusual items
28,17 მლრდ.
133,86 მლრ.
-455,02 მლრ.
162,72 მლრ.
EBT excluding unusual items
128,86 მლრ.
114,17 მლრ.
71,49 მლრდ.
161,92 მლრ.
Income tax expense
39,90 მლრდ.
30,13 მლრდ.
-86,62 მლრდ.
49,46 მლრდ.
Effective tax rate
141,64%
22,51%
19,04%
30,40%
Other operating expenses
16,12 მლრდ.
67,13 მლრდ.
-64,27 მლრდ.
53,17 მლრდ.
Net income
-11,80 მლრდ.
103,64 მლრ.
-368,47 მლრ.
113,20 მლრ.
Net profit margin
-1,06%
8,70%
-33,66%
9,28%
Earnings per share
-
-
-
-
Interest and investment income
43,92 მლრდ.
181,35 მლრ.
-
24,61 მლრდ.
Interest expense
-161,10 მლრ.
-
-239,63 მლრ.
-35,70 მლრდ.
Net interest expenses
-117,18 მლრ.
181,35 მლრ.
-239,63 მლრ.
-11,09 მლრდ.
Depreciation and amortization charges
-
-
-
-
EBITDA
355,15 მლრ.
319,89 მლრ.
192,73 მლრ.
363,66 მლრ.
Gain or loss from assets sale
303,00 მლნ.
358,00 მლნ.
1,46 მლრდ.
-6,00 მლრდ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები